Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ninerafaxstat in Non-obstructive HCM
NCT04826185Phase 2Completed
- Sponsor
- Imbria Pharmaceuticals
- Start
- Jun 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Ninerafaxstat with Placebo (2 arms). Primary endpoint: Incidence and severity of treatment emergent adverse events (TEAEs) and SAEs at 14 weeks. Started Jun 2021; status: completed.
02
Drugs
ninerafaxstat
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT04826185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04826185.